Annual report for Sanofi India Ltd. for FY-2017
27-02-2017
FY16 results on Feb 27, 2017
Sanofi India Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 27, 2017, inter alia, to:1. Approve the audited accounts for the year ended December 31, 2016.2. Recommend final dividend for the period mentioned above.15-02-2017
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Sanofi India Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.18-01-2017
Shareholding for the Period Ended December 31, 2016
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here17-01-2017
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aberdeen Asset Management Asia Ltd06-01-2017
Sanofi India to collaborate with NIPER Kolkata for pharma education and R
Two sides will be collaborate in the areas of pharmaceuticals and consumer healthcare products to cater to the current and future needs of the industry18-11-2016
Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research
Sanofi India Ltd has informed BSE regarding a Press Release dated November 17, 2016 titled "Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research".17-11-2016
Outcome of Board Meeting (Change in Company Secretary, Compliance Officer & KMP)
Sanofi India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 07, 2016 approved appointment of Mr. Girish Tekchandani as Company Secretary and Key Managerial Personnel with effect from November 08, 2016 in place of Mr. K Subramani who will be retiring from the services of the company at the end of December 2016, and will cease to be Company Secretary and Key Managerial Personnel at the end of business hour on November 07, 2016....07-11-2016
Announces Q3 results (Standalone) & Limited Review Report for the quarter ended September 30, 2016
Sanofi India Ltd has announced the Un-Audited Standalone results for the quarter ended September 30, 2016 :The Company has posted a net profit of Rs. 806 million for the quarter ended September 30, 2016 as compared to Rs. 725 million for the quarter ended September 30, 2015. Total Income has increased from Rs. 5952 million for the quarter ended September 30, 2015 to Rs. 6390 million for the quarter ended September 30, 2016.07-11-2016
Q3 results on Nov 07, 2016
Sanofi India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 07, 2016 for approving the unaudited financial results for the quarter ended September 30, 2016 (Q3).21-10-2016